Welcome to our dedicated page for Breeze Holdings news (Ticker: BRZH), a resource for investors and traders seeking the latest updates and insights on Breeze Holdings stock.
Breeze Holdings Acquisition Corp. (BRZH) is a special purpose acquisition company in the Financial Services sector, classified as a shell company. Its public communications focus on its efforts to complete a business combination with one or more operating businesses, making its news flow centered on transaction milestones, shareholder votes, and listing developments.
News about BRZH has included updates on its trading venue, such as the announcement that its common stock and warrants began trading on the OTCQX Best Market under the symbols BRZH and BRZHW. The company has also issued releases about its search for a suitable target, including the termination of a proposed business combination with TV Ammo, Inc. and its stated intention to continue pursuing another transaction.
A major focus of recent news has been Breeze’s definitive agreement to merge with YD Biopharma Limited, a clinical-stage biopharmaceutical company. Coverage describes the structure of the proposed merger, the creation of a new Cayman holding company expected to be named YD Biopharma Holdings Limited, and plans for the combined company to be listed on the Nasdaq Capital Market. Subsequent news detailed the shareholder vote in which Breeze’s stockholders approved the business combination with YD Biopharma.
On this page, readers can review announcements related to BRZH’s business combination process, including transaction agreements, shareholder meeting results, and expectations for the combined company to operate as YD Bio Limited with an anticipated Nasdaq ticker "YDES," subject to closing conditions. For investors and researchers tracking SPAC activity and the evolution of this particular transaction, the BRZH news feed offers a focused archive of these corporate developments.
Breeze Holdings Acquisition Corp. (OTCQX: BRZH) shareholders have approved the business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company focused on vaccines and therapeutic biologics. The special meeting saw 3,128,495 shares represented, with 3,127,474 shares voting in favor of the merger.
The combined entity will be renamed to YD Bio Limited and is expected to trade on the Nasdaq under the ticker symbol "YDES". The transaction is anticipated to close within two weeks, pending customary closing conditions.
Breeze Holdings Acquisition Corp (OTCQX: BRZH) has entered into a definitive agreement to merge with YD Biopharma , a clinical-stage biopharmaceutical company focusing on cancer prevention diagnostics and exosome-based therapeutics. The combined company, with an estimated enterprise value of nearly $700 million, is expected to be listed on the Nasdaq Capital Market by early 2025.
YD Biopharma has recently obtained patents, technology, and U.S. authorization for core methylation detection of pancreatic cancer, and is in the process of acquiring licenses for breast cancer detection technology. The company also specializes in ophthalmology cellular drug development and serves as a clinical testing drug supplier for Novartis.
The transaction, approved by both companies' boards, aims to provide YD Biopharma with capital to expand production and continue development, approval, and launch of new technologies. The combined company will be led by YD Biopharma's current management team.
Breeze Holdings Acquisition Corp. (OTCQX: BRZH) has announced its approval to trade on the OTCQX Best Market. The company's common stock and warrants, under tickers 'BRZH' and 'BRZHW' respectively, began trading on August 21, 2024. This update follows the termination of a previously planned business combination with TV Ammo, Inc., as reported in a Form 8-K filing on August 9, 2024.
Breeze's management team is actively pursuing a new business combination transaction and has until December 26, 2024 to complete one, as per SEC requirements. The company plans to provide further updates as progress is made in identifying a potential target company.